On March 7, 2024, 180 Life Sciences Corp. announced significant changes to its Board of Directors. Sir Marc Feldmann, Ph.D., resigned from his position on the Board, effective immediately. His resignation was not due to any disagreements with the company's operations or practices. Concurrently, the company appointed Omar Jimenez and Ryan L. Smith as new independent directors, effective the same date. Both appointees will serve as Class II directors until the 2024 Annual Meeting of Stockholders. The Board also adjusted its size to five members. Jimenez, with extensive financial and compliance experience, will serve as the audit committee financial expert and chair the Audit Committee. Smith, with a background in business and public company fundraising, will chair the Compensation Committee and Nominating...Show More

On March 7, 2024, 180 Life Sciences Corp. announced significant changes to its Board of Directors. Sir Marc Feldmann, Ph.D., resigned from his position on the Board, effective immediately. His resignation was not due to any disagreements with the company's operations or practices. Concurrently, the company appointed Omar Jimenez and Ryan L. Smith as new independent directors, effective the same date. Both appointees will serve as Class II directors until the 2024 Annual Meeting of Stockholders. The Board also adjusted its size to five members. Jimenez, with extensive financial and compliance experience, will serve as the audit committee financial expert and chair the Audit Committee. Smith, with a background in business and public company fundraising, will chair the Compensation Committee and Nominating and Corporate Governance Committee. The company plans to enter into standard Indemnification Agreements with the new directors, similar to those with other directors, to cover certain legal expenses. These board changes have resulted in a majority of independent members on the Board and all three committees being fully independent, aligning with Nasdaq rules.